The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I study of concomitant galinpepimut-s (GPS) in combination with nivolumab (nivo) in patients (pts) with WT1+ ovarian cancer (OC) in second or third remission.
 
Roisin Eilish O'Cearbhaill
Consulting or Advisory Role - Clovis Oncology; Tesaro
Research Funding - Janssen Oncology (Inst); Juno Therapeutics (Inst); Ludwig Institute for Cancer Research (Inst); OncoMed (Inst); Sellas Life Sciences (Inst)
 
Sacha Gnjatic
Consulting or Advisory Role - B4CC; Third Rock Ventures
Research Funding - Immune Design; Janssen Research & Development
Patents, Royalties, Other Intellectual Property - Patents on NY-ESO-1 immune compositions and peptides.
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Carol Aghajanian
Consulting or Advisory Role - Cerulean Pharma; Clovis Oncology; Clovis Oncology; Oxigene; Oxigene; Tesaro
 
Alexia Iasonos
No Relationships to Disclose
 
Jason A. Konner
Consulting or Advisory Role - Clovis Oncology; Genentech/Roche
Research Funding - AstraZeneca/MedImmune; Genentech/Roche; TapImmune Inc.
 
Nicolle Losada
Research Funding - Sellas Life Sciences
 
Debra Sarasohn
No Relationships to Disclose
 
Teresa Rasalan
No Relationships to Disclose
 
William P. Tew
No Relationships to Disclose
 
Dmitriy Zamarin
Employment - Acorda Therapeutics (I)
Consulting or Advisory Role - BioMed Valley Discoveries; Merck; PsiOxus Therapeutics; Synlogic
Research Funding - Merck
Patents, Royalties, Other Intellectual Property - I hold a patent regarding the use of recombinant Newcastle Disease Virus (NDV) for cancer therapy. (Inst)
 
Phillip Wong
Consulting or Advisory Role - Merck
Patents, Royalties, Other Intellectual Property - Receive small annual royalty payments from the University of Washington for a monoclonal antibody that was developed during my graduate studies there.
 
Paul Sabbatini
Honoraria - UpToDate
Research Funding - Bristol-Myers Squibb (Inst); Ludwig Institute for Cancer Research (Inst)